IL148826A0 - Cell-based gene therapy for the pulmonary system - Google Patents

Cell-based gene therapy for the pulmonary system

Info

Publication number
IL148826A0
IL148826A0 IL14882699A IL14882699A IL148826A0 IL 148826 A0 IL148826 A0 IL 148826A0 IL 14882699 A IL14882699 A IL 14882699A IL 14882699 A IL14882699 A IL 14882699A IL 148826 A0 IL148826 A0 IL 148826A0
Authority
IL
Israel
Prior art keywords
cell
based gene
gene therapy
patient
pulmonary system
Prior art date
Application number
IL14882699A
Other languages
English (en)
Original Assignee
An Go Gen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by An Go Gen Inc filed Critical An Go Gen Inc
Publication of IL148826A0 publication Critical patent/IL148826A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
    • C12Y114/13039—Nitric-oxide synthase (NADPH dependent) (1.14.13.39)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL14882699A 1999-09-23 1999-09-23 Cell-based gene therapy for the pulmonary system IL148826A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA1999/000869 WO2001021184A1 (fr) 1999-09-23 1999-09-23 Therapie genique cellulaire pour le systeme pulmonaire

Publications (1)

Publication Number Publication Date
IL148826A0 true IL148826A0 (en) 2002-09-12

Family

ID=4173386

Family Applications (3)

Application Number Title Priority Date Filing Date
IL14882699A IL148826A0 (en) 1999-09-23 1999-09-23 Cell-based gene therapy for the pulmonary system
IL14882602A IL148826A (en) 1999-09-23 2002-03-21 Genetically modified mammalian cells and use thereof for the pulmonary system
IL192893A IL192893A (en) 1999-09-23 2008-07-17 Mammalian cells with genetic alterations and their use in the pulmonary system

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL14882602A IL148826A (en) 1999-09-23 2002-03-21 Genetically modified mammalian cells and use thereof for the pulmonary system
IL192893A IL192893A (en) 1999-09-23 2008-07-17 Mammalian cells with genetic alterations and their use in the pulmonary system

Country Status (11)

Country Link
EP (2) EP1839667B1 (fr)
JP (1) JP2003509463A (fr)
AT (1) ATE364387T1 (fr)
AU (1) AU5724499A (fr)
BR (1) BR9917500A (fr)
CA (1) CA2383093A1 (fr)
DE (1) DE69936320T2 (fr)
ES (1) ES2546937T3 (fr)
IL (3) IL148826A0 (fr)
MX (1) MXPA02003131A (fr)
WO (1) WO2001021184A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11975030B2 (en) 2019-03-19 2024-05-07 Figene, Llc Treatment of chronic obstructive pulmonary disease and lung degeneration using activated fibroblasts and exosome derivatives thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219740A (en) * 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
EP0456640A1 (fr) * 1988-12-13 1991-11-21 UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Cellules endotheliales modifiees par genie genetique et utilisation de ces cellules
US5240846A (en) * 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
WO1992015676A1 (fr) * 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Therapie genique par les cellules somatiques
WO1993013807A1 (fr) * 1992-01-10 1993-07-22 Georgetown University Procede permettant d'administrer des cellules endotheliales produites par genie genetique au niveau de sites d'angiogenese afin d'effectuer une therapie genetique
CA2086844A1 (fr) * 1993-01-07 1994-07-08 Ian D. Dube Methode et produit de transfert de genes dans des cellules
CA2260771A1 (fr) * 1996-07-17 1998-01-22 The General Hospital Corporation Procede servant a provoquer la vasodilatation et a traiter l'hypertension pulmonaire au moyen du transfert provoque par adenovirus du gene de synthase d'oxyde nitrique
CA2270286C (fr) * 1996-11-01 2009-03-03 Eurogene Limited Utilisation therapeutique d'un facteur de croissance et systeme d'administration, en particulier pour le traitement de l'hyperplasie endoveineuse
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
EP0893493A3 (fr) * 1997-07-21 2002-12-04 Aventis Pharma Deutschland GmbH Cellules génétiquement modifiées et leur application pour la prévention ou traitement de maladies
US6147109A (en) * 1997-10-14 2000-11-14 The General Hospital Corporation Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
AU767662B2 (en) * 1998-02-06 2003-11-20 Collateral Therapeutics, Inc. Variants of the angiogenic factor vascular endothelial cell growth factor: VEGF
CA2266805C (fr) * 1998-03-27 2015-04-28 An-Go-Gen Inc. Therapie genique cellulaire dans le traitement des affections pulmonaires
CA2227425A1 (fr) * 1998-03-27 1999-09-27 An-Go-Gen Inc. Therapie genique cellulaire

Also Published As

Publication number Publication date
ATE364387T1 (de) 2007-07-15
IL192893A (en) 2014-03-31
ES2546937T3 (es) 2015-09-30
EP1839667B1 (fr) 2015-06-17
IL148826A (en) 2010-12-30
JP2003509463A (ja) 2003-03-11
EP1839667A2 (fr) 2007-10-03
EP1220679A1 (fr) 2002-07-10
DE69936320D1 (de) 2007-07-26
BR9917500A (pt) 2002-05-21
EP1839667A3 (fr) 2010-04-14
CA2383093A1 (fr) 2001-03-29
EP1220679B1 (fr) 2007-06-13
WO2001021184A1 (fr) 2001-03-29
AU5724499A (en) 2001-04-24
MXPA02003131A (es) 2003-08-20
DE69936320T2 (de) 2008-02-21
IL192893A0 (en) 2009-02-11

Similar Documents

Publication Publication Date Title
NZ505011A (en) Expression vectors and cell lines expressing VEGF-D and method of treating melanomas
DE69331526T2 (de) Adenovirus gelenkter gen-transfer zum herz- und glatten vaskularen muskel
IL177228A0 (en) Use of a vector for the manufacture of a medicament for treating gaucher disease
NZ266475A (en) Use of recombinant adenovirus of animal origin in making pharmaceutical composition
GR3034758T3 (en) System and method for transplantation of cells.
DE69635899D1 (de) Polypeptid, das die differenzierung unterdrueckt
PL340096A1 (en) Methods of treating hypercoagulability states or hypoproteinaemia in respect to c protein
ATE385810T1 (de) Verwendung von dna oder rna zur herstellung eines medikaments zur behandlung von tumoren
GR3024263T3 (en) Methods and deoxyribonucleic acid for the preparation of tissue factor protein
MX9603927A (es) Metodo para la estimulacion de hematopoyesis con hemoglobina.
SE9702860L (sv) Användning av en stam av Lactobacillus för tillverkning av ett läkemedel för reduktion av fibrinogenhalten i blod
PT1137762E (pt) Tratamento da doença de pompe
GR3032457T3 (en) Compositions and methods for modulating rna activity through modification of the 5' cap structure of rna.
GR3036438T3 (en) Medicinal combination useful for in vivo exogenic transfection and expression
MD545G2 (ro) Preparat medicamentos
IL192893A0 (en) Cell-based gene therapy for the pulmonary system
AU6820190A (en) Method of treating fibrotic disorders
HU910436D0 (en) Process for the production of medical preparations for treating apnoea during sleep
NZ299257A (en) Treating purulent material (eg pulmonary disease) accumulation in patients using deamidated DNase
WO2000017375A3 (fr) Procede de traitement de l'hemophilie par therapie genique in vivo a l'aide de vecteurs retroviraux
GEP20012489B (en) Use of Natural Human α-Interferon
GB0202410D0 (en) Treatment of IL deficiencies
James Gallo starts major AIDS research institute in Baltimore
CA2165271A1 (fr) Reduction du tissu adipeux
Qiang et al. Effect of auriculoacupuncture on life quality of patients with malignant tumors